Conor Medsystems (Menlo Park, California) said that on Feb. 13 it received a letter from Nasdaq indicating that the company had remedied its previous non-compliance with the audit committee composition requirements set forth in Nasdaq Marketplace Rule 4350(d) with the appointment of Steven Gerber to the audit committee on Feb. 10.

The company was not in compliance with this rule for three days as a result of the resignation of George Milne from the board on Feb. 6, but Nasdaq indicated in its letter that the company is now in compliance with the rule.

Conor Medsystems develops controlled vascular drug-delivery technologies, and has initially focused on the development of drug-eluting stents to treat coronary artery disease.

No Comments